STOCK TITAN

[Form 4] Baxter International Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Alok Sonig, EVP & Group President, Pharma at Baxter International (BAX), reported a transaction on 09/02/2025. He relinquished 3,191 shares of Baxter common stock at a price of $24.17 per share to cover tax withholding tied to the delivery of vested restricted stock units granted on 09/01/2022. After the transaction, the reporting person beneficially owns 128,219 shares, which the filing notes includes automatic dividend reinvestment. The sale was reported on a Form 4 signed by an attorney-in-fact on 09/04/2025.

Alok Sonig, EVP & Group President, Pharma di Baxter International (BAX), ha riportato un'operazione il 09/02/2025. Ha ceduto 3.191 azioni ordinarie Baxter al prezzo di $24,17 per azione per coprire la ritenuta fiscale legata alla consegna di unità azionarie vincolate (RSU) maturate e assegnate il 01/09/2022. Dopo l'operazione, la persona segnalante detiene beneficiariamente 128.219 azioni, che la comunicazione indica comprendono il reinvestimento automatico dei dividendi. La vendita è stata riportata su un Modulo 4 firmato da un procuratore il 09/04/2025.

Alok Sonig, EVP & Group President, Pharma en Baxter International (BAX), declaró una transacción el 02/09/2025. Cedió 3.191 acciones ordinarias de Baxter a un precio de $24,17 por acción para cubrir retenciones fiscales relacionadas con la entrega de unidades restringidas de acciones (RSU) adquiridas el 01/09/2022. Tras la operación, la persona informante posee beneficiariamente 128.219 acciones, que el informe señala incluyen el reinversión automática de dividendos. La venta fue informada en un Formulario 4 firmado por un apoderado el 04/09/2025.

Alok Sonig, Baxter International (BAX) 의 EVP 겸 그룹 사장(Pharma),가 2025-09-02에 거래를 보고했습니다. 그는 2022-09-01에 부여된 확정된 제한주식단위(RSU)의 지급과 관련된 세금 원천징수를 충당하기 위해 Baxter 보통주 3,191주를 주당 $24.17에 처분했습니다. 거래 후 보고인은 자동 배당 재투자를 포함하여 보고서에 명시된 128,219주를 실질적으로 보유하고 있습니다. 이 매도는 2025-09-04에 법정대리인이 서명한 Form 4에 보고되었습니다.

Alok Sonig, EVP & Group President, Pharma chez Baxter International (BAX), a déclaré une opération le 02/09/2025. Il a cédé 3 191 actions ordinaires Baxter au prix de 24,17 $ par action pour couvrir la retenue d'impôt liée à la remise d'unités d'actions restreintes (RSU) devenues acquises et attribuées le 01/09/2022. Après l'opération, la personne déclarant détient à titre bénéficiaire 128 219 actions, le dépôt indiquant que cela inclut le réinvestissement automatique des dividendes. La vente a été déclarée sur un formulaire 4 signé par un mandataire le 04/09/2025.

Alok Sonig, EVP & Group President, Pharma bei Baxter International (BAX), meldete eine Transaktion am 02.09.2025. Er veräußerte 3.191 Stammaktien von Baxter zum Preis von $24,17 je Aktie, um die steuerliche Einbehaltung im Zusammenhang mit der Auszahlung ausgefallener Restricted Stock Units (RSUs), gewährt am 01.09.2022, zu begleichen. Nach der Transaktion besitzt die meldende Person wirtschaftlich 128.219 Aktien, wobei die Meldung angibt, dass dies die automatische Wiederanlage von Dividenden einschließt. Der Verkauf wurde in einem Formblatt 4 gemeldet, das am 04.09.2025 von einem Bevollmächtigten unterzeichnet wurde.

Positive
  • Continued significant ownership: Reporting person still beneficially owns 128,219 shares after the transaction
  • Transaction clearly explained: Filing specifies the shares were forfeited to cover tax withholding from vested RSUs granted on 09/01/2022
Negative
  • Shares disposed: 3,191 shares were surrendered on 09/02/2025
  • Sale price disclosed: Shares covered withholding at $24.17 per share, indicating a realized reduction in holding

Insights

TL;DR: Routine tax-withholding disposition of vested RSUs; continues to hold substantial shares.

The Form 4 documents a standard tax-withholding sale following RSU delivery rather than a voluntary open-market divestiture. The report identifies the grant date of the RSUs (09/01/2022) and explains that 3,191 shares were forfeited to cover withholding obligations, leaving 128,219 shares beneficially owned. This is a common administrative transaction and does not indicate a change in control or a strategic shift by management.

TL;DR: Small-scale disposition at $24.17/share tied to compensation vesting; minimal investor impact.

The disposal was executed at $24.17 per share on 09/02/2025 and is explicitly for tax withholding resulting from vested restricted stock units. The filing discloses continued beneficial ownership of 128,219 shares, including reinvested dividends. Given the transaction size relative to typical insider holdings and the stated purpose, this should be considered routine and unlikely to materially affect investor valuation.

Alok Sonig, EVP & Group President, Pharma di Baxter International (BAX), ha riportato un'operazione il 09/02/2025. Ha ceduto 3.191 azioni ordinarie Baxter al prezzo di $24,17 per azione per coprire la ritenuta fiscale legata alla consegna di unità azionarie vincolate (RSU) maturate e assegnate il 01/09/2022. Dopo l'operazione, la persona segnalante detiene beneficiariamente 128.219 azioni, che la comunicazione indica comprendono il reinvestimento automatico dei dividendi. La vendita è stata riportata su un Modulo 4 firmato da un procuratore il 09/04/2025.

Alok Sonig, EVP & Group President, Pharma en Baxter International (BAX), declaró una transacción el 02/09/2025. Cedió 3.191 acciones ordinarias de Baxter a un precio de $24,17 por acción para cubrir retenciones fiscales relacionadas con la entrega de unidades restringidas de acciones (RSU) adquiridas el 01/09/2022. Tras la operación, la persona informante posee beneficiariamente 128.219 acciones, que el informe señala incluyen el reinversión automática de dividendos. La venta fue informada en un Formulario 4 firmado por un apoderado el 04/09/2025.

Alok Sonig, Baxter International (BAX) 의 EVP 겸 그룹 사장(Pharma),가 2025-09-02에 거래를 보고했습니다. 그는 2022-09-01에 부여된 확정된 제한주식단위(RSU)의 지급과 관련된 세금 원천징수를 충당하기 위해 Baxter 보통주 3,191주를 주당 $24.17에 처분했습니다. 거래 후 보고인은 자동 배당 재투자를 포함하여 보고서에 명시된 128,219주를 실질적으로 보유하고 있습니다. 이 매도는 2025-09-04에 법정대리인이 서명한 Form 4에 보고되었습니다.

Alok Sonig, EVP & Group President, Pharma chez Baxter International (BAX), a déclaré une opération le 02/09/2025. Il a cédé 3 191 actions ordinaires Baxter au prix de 24,17 $ par action pour couvrir la retenue d'impôt liée à la remise d'unités d'actions restreintes (RSU) devenues acquises et attribuées le 01/09/2022. Après l'opération, la personne déclarant détient à titre bénéficiaire 128 219 actions, le dépôt indiquant que cela inclut le réinvestissement automatique des dividendes. La vente a été déclarée sur un formulaire 4 signé par un mandataire le 04/09/2025.

Alok Sonig, EVP & Group President, Pharma bei Baxter International (BAX), meldete eine Transaktion am 02.09.2025. Er veräußerte 3.191 Stammaktien von Baxter zum Preis von $24,17 je Aktie, um die steuerliche Einbehaltung im Zusammenhang mit der Auszahlung ausgefallener Restricted Stock Units (RSUs), gewährt am 01.09.2022, zu begleichen. Nach der Transaktion besitzt die meldende Person wirtschaftlich 128.219 Aktien, wobei die Meldung angibt, dass dies die automatische Wiederanlage von Dividenden einschließt. Der Verkauf wurde in einem Formblatt 4 gemeldet, das am 04.09.2025 von einem Bevollmächtigten unterzeichnet wurde.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Sonig Alok

(Last) (First) (Middle)
ONE BAXTER PARKWAY

(Street)
DEERFIELD IL 60015

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BAXTER INTERNATIONAL INC [ BAX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP,Group President,Pharma
3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, $1 par value 09/02/2025 F 3,191(1) D $24.17 128,219(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the delivery of shares on September 2, 2025 from the settlement of vested restricted stock units granted on September 1, 2022
2. Total includes the automatic reinvestment of dividends.
Remarks:
/s/ Kimberly Olson, as attorney in-fact for Alok Sonig 09/04/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Alok Sonig report on the BAX Form 4?

The report shows 3,191 shares were forfeited on 09/02/2025 at $24.17 per share to cover tax withholding from vested RSUs.

How many Baxter (BAX) shares does the reporting person own after this transaction?

The filing reports beneficial ownership of 128,219 shares following the transaction, which includes automatic dividend reinvestment.

Why were the shares disposed of according to the Form 4?

The filing states the shares were forfeited to cover withholding taxes incurred upon delivery of vested restricted stock units granted on 09/01/2022.

When was the Form 4 signed and by whom?

The Form 4 was signed on behalf of the reporting person by an attorney-in-fact, Kimberly Olson, on 09/04/2025.

Does this Form 4 indicate a large open-market sale by an insider?

No. The filing describes a tax-withholding forfeiture associated with RSU delivery, not an open-market divestiture.
Baxter Intl Inc

NYSE:BAX

BAX Rankings

BAX Latest News

BAX Latest SEC Filings

BAX Stock Data

12.11B
511.70M
0.28%
99.17%
3.72%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
DEERFIELD